Please login to the form below

Not currently logged in
Email:
Password:

VX-135

This page shows the latest VX-135 news and features for those working in and with pharma, biotech and healthcare.

Gilead files oral hepatitis C drug sofosbuvir in US

Gilead files oral hepatitis C drug sofosbuvir in US

However, BMS has recently signed a deal with Vertex Pharmaceuticals to partner on a clinical investigating a combination of the BMS candidate daclatasvir and Vertex' uridine nucleotide analogue VX-135.

Latest news

  • BMS and Vertex partner on oral hepatitis treatment BMS and Vertex partner on oral hepatitis treatment

    BMS and Vertex partner on oral hepatitis treatment. Will investigate combination of daclatasvir and VX-135. ... VX-135 is a uridine nucleotide analogue that, like BMS-986094, is designed to affect the NS5B polymerase to inhibit the replication the

  • Vertex reports fatal reactions with hepatitis C drug Vertex reports fatal reactions with hepatitis C drug

    The cornerstone of Vertex' all-oral regimens is VX-135, a nucleotide polymerase inhibitor that is being tested alongside a range of other directly-acting antivirals, including GlaxoSmithKline's NS5A inhibitor ... Vertex is, however, also planning to test

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics